Molecular Biology Reports

, Volume 46, Issue 2, pp 2417–2425 | Cite as

EGF+61 A>G polymorphism is not associated with lung cancer risk in the Brazilian population

  • Ana Carolina Laus
  • Flavia Escremim de Paula
  • Marcos Alves de Lima
  • Carolina Dias Carlos
  • Izabela Natalia Faria Gomes
  • Pedro de Marchi
  • Jenna Kadja Neves Valente
  • Ana Beatriz Maringolo Pioltini
  • José Elias Miziara
  • Carlos Maciel da Silva
  • Luciano de Souza Viana
  • Cristovam Scapulatempo-Neto
  • Rui Manuel ReisEmail author
Original Article


Epidermal growth factor (EGF) and its receptor (EGFR) play an important role in lung carcinogenesis. A functional single nucleotide polymorphism (SNP) in EGF promoter region (EGF+61 A>G—rs4444903) has been associated with cancer susceptibility. Yet, in lung cancer, the EGF+61 A>G role is unclear. The aim of this study was to evaluate the risk of lung cancer associated with EGF+61 A>G SNP in the Brazilian population. For that, 669 lung cancer patients and 1104 controls were analyzed. EGF+61 A>G genotype was assessed by PCR-RFLP and TaqMan genotyping assay. Both patients and controls were in Hardy–Weinberg equilibrium. As expected, uni- and multivariate analyses showed that tobacco consumption and age were significant risk factors for lung cancer. The genotype frequencies in lung cancer patients were 27.3% of AA, 47.4% of AG and 25.3% of GG, and for controls were 25.3% of AA, 51.6% of AG and 23.1% of GG. The allele frequencies were 51.1% of A and 48.9% of G for both cases and controls. No significant differences for the three genotypes (AA, AG and GG—codominant model) were observed between cases and controls. We then grouped AG and GG (recessive model) genotypes, as well as AA and AG (dominant model), and again, no significant differences were also found. This is the largest study to explore EGF+61 A>G polymorphism association with lung cancer risk and suggests that this SNP is not a risk factor for lung cancer in the Brazilian population.


Lung cancer SNP Risk factor EGF+61 A>G polymorphism 



The authors would like to thank Barretos Cancer Hospital Research Support Department (NAP) for sample collection and Barretos Cancer Hospital Biobank for sample processing.


This study was partially supported by FINEP - CT-INFRA (02/2010) and Barretos Cancer Hospital Research Fund (PAIP).

Compliance with ethical standards

Conflict of interest

None of the authors have any financial or non-financial conflict of interests.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration or its later amendments or comparable ethical standards. The study was approved by Barretos Cancer Hospital Ethics Committee (#596/2012).

Informed consent

Signed informed consents were obtained from all control individuals and cases included in the study that provided blood samples. From the FFPE cases, due to the retrospective nature of the study, the Barretos Cancer Hospital Ethics Committee exempted informed consent.

Supplementary material

11033_2019_4702_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (DOCX 13 KB)


  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. Google Scholar
  2. 2.
    INCA (2018) Estimativas 2018. In. INCA. Accessed 04 Oct 2018
  3. 3.
    DATASUS (2018) Sistema de informações sobre mortalidade. In: Ministério da Saúde. Accessed 14 Jan 2019
  4. 4.
    Akhtar N, Bansal JG (2017) Risk factors of Lung Cancer in nonsmoker. Curr Probl Cancer. Google Scholar
  5. 5.
    Wee P, Wang Z (2017) Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel). Google Scholar
  6. 6.
    Dibble CC, Cantley LC (2015) Regulation of mTORC1 by PI3K signaling. Trends Cell Biol 25(9):545–555. CrossRefGoogle Scholar
  7. 7.
    Normanno N, Bianco C, De Luca A, Salomon DS (2001) The role of EGF-related peptides in tumor growth. Front Biosci J Virtual Libr 6:D685–D707CrossRefGoogle Scholar
  8. 8.
    TCGA The Cancer Genome Atlas. Accessed 28 Sept 2018
  9. 9.
    ICGC International Cancer Genome Consortium.
  10. 10.
    Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ (2017) Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 7(6):596–609. CrossRefGoogle Scholar
  11. 11.
    Jurisic V, Obradovic J, Pavlovic S, Djordjevic N (2018) Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. Anal Cell Pathol 2018:6192187. CrossRefGoogle Scholar
  12. 12.
    Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, Hutchinson PE, Osborne JE, Lear JT, Smith AG, Hutchinson IV (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359(9304):397–401. CrossRefGoogle Scholar
  13. 13.
    Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, Pardal F, Suriano G, Machado JC, Lopes JM, Reis RM (2007) Association between functional EGF + 61 polymorphism and glioma risk. Clin Cancer Res Off J Am Assoc Cancer Res 13(9):2621–2626. CrossRefGoogle Scholar
  14. 14.
    Wu SJ, Jiang SY, Wu J, Xiong GL (2015) Association between EGF+61 A>G polymorphism and gastric cancer risk: A meta-analysis. J Huazhong Univ Sci Technol Med Sci 35(3):327–332. CrossRefGoogle Scholar
  15. 15.
    Sun S, Jin GJ, Zhao Y, Kang H (2015) Association between the epidermal growth factor 61*A/G polymorphism and hepatocellular carcinoma risk: a meta-analysis. Asian Pac J Cancer Prev APJCP 16(7):3009–3014CrossRefGoogle Scholar
  16. 16.
    Chen X, Yang G, Zhang D, Zhang W, Zou H, Zhao H, Zhang X, Zhao S (2014) Association between the epidermal growth factor + 61 G/A polymorphism and glioma risk: a meta-analysis. PLoS ONE 9(4):e95139. CrossRefGoogle Scholar
  17. 17.
    Lim YJ, Kim JW, Song JY, Hong MS, Jin SY, Yoon SH, Park HJ, Choe BK, Lee JJ, Yim SV, Hong SI, Baik HH, Ha E, Park YH (2005) Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett 374(3):157–160. CrossRefGoogle Scholar
  18. 18.
    Kang HG, Choi JE, Lee WK, Kam S, Cha SI, Kim CH, Jung TH, Park JY (2007) +61 A>G polymorphism in the EGF gene does not increase the risk of lung cancer. Respirology 12:902–905. CrossRefGoogle Scholar
  19. 19.
    de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, Almeida MI, Cunha J, Oliveira P, Hespanhol V, Reis RM (2012) Association between EGF + 61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study. Tumour Biol 33(5):1341–1348. CrossRefGoogle Scholar
  20. 20.
    Masroor M, Amit J, Javid J, Mir R, Prasant Y, Imtiyaz A, Mariyam Z, Mohan A, Ray PC, Saxena A (2015) Clinical implication of EGF A61G polymorphism in the risk of non small cell lung adenocarcinoma patients: a case control study. Asian Pac J Cancer Prev 16(17):7529–7534CrossRefGoogle Scholar
  21. 21.
    Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR (2015) A global reference for human genetic variation. Nature 526(7571):68–74. CrossRefGoogle Scholar
  22. 22.
    Cui L, Pan XM, Ma CF, Shang-Guan J, Yu HB, Chen GX, Wang J (2010) Association between epidermal growth factor polymorphism and esophageal squamous cell carcinoma susceptibility. Dig Dis Sci 55(1):40–45. CrossRefGoogle Scholar
  23. 23.
    Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A, Pina F, Calais-da-Silva F, Medeiros R (2008) Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res 14(11):3367–3371. CrossRefGoogle Scholar
  24. 24.
    Wu GY, Hasenberg T, Magdeburg R, Bonninghoff R, Sturm JW, Keese M (2009) Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J Surg 33(1):124–129. CrossRefGoogle Scholar
  25. 25.
    Li TF, Ren KW, Liu PF (2012) Meta-analysis of epidermal growth factor polymorphisms and cancer risk: involving 9779 cases and 15,932 controls. DNA Cell Biol 31(4):568–574. CrossRefGoogle Scholar
  26. 26.
    Callegari-Jacques SM, Grattapaglia D, Salzano FM, Salamoni SP, Crossetti SG, Ferreira ME, Hutz MH (2003) Historical genetics: spatiotemporal analysis of the formation of the Brazilian population. Am J Hum Biol 15(6):824–834. CrossRefGoogle Scholar
  27. 27.
    Zhang YM, Cao C, Liang K (2010) Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a meta-analysis. Cancer Epidemiol 34(2):150–156. CrossRefGoogle Scholar
  28. 28.
    Rose S, Laan MJ (2009) Why match? Investigating matched case-control study designs with causal effect estimation. Int J Biostat 5(1):Article 1. CrossRefGoogle Scholar
  29. 29.
    Elez-Burnjakovic N, Ugrin M, Obradovic J, Miletic N, Racic M, Kulic M, Pavlovic S, Jurisic V (2018) Distribution of EGFR SNPs - 191C/A and 181946G/A in patients with lung cancer depending on smoking status in the Republic of Srpska, Bosnia and Herzegovina. J BUON Off J Balk Union Oncol 23(2):384–390Google Scholar
  30. 30.
    Bashir NA, Ragab ES, Khabour OF, Khassawneh BY, Alfaqih MA, Momani JA (2018) The Association between Epidermal Growth Factor Receptor (EGFR) Gene Polymorphisms and Lung Cancer Risk. Biomolecules. Google Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Ana Carolina Laus
    • 1
  • Flavia Escremim de Paula
    • 1
  • Marcos Alves de Lima
    • 2
  • Carolina Dias Carlos
    • 1
  • Izabela Natalia Faria Gomes
    • 1
  • Pedro de Marchi
    • 3
  • Jenna Kadja Neves Valente
    • 3
  • Ana Beatriz Maringolo Pioltini
    • 3
  • José Elias Miziara
    • 4
  • Carlos Maciel da Silva
    • 4
  • Luciano de Souza Viana
    • 3
  • Cristovam Scapulatempo-Neto
    • 5
  • Rui Manuel Reis
    • 1
    • 6
    • 7
    Email author
  1. 1.Molecular Oncology Research CenterBarretos Cancer HospitalBarretosBrazil
  2. 2.Epidemiology and Biostatistics DepartmentBarretos Cancer HospitalBarretosBrazil
  3. 3.Medical Oncology DepartmentBarretos Cancer HospitalBarretosBrazil
  4. 4.Surgery DepartmentBarretos Cancer HospitalBarretosBrazil
  5. 5.Pathology DepartmentBarretos Cancer HospitalBarretosBrazil
  6. 6.Life and Health Sciences Research Institute (ICVS), School of MedicineUniversity of MinhoBragaPortugal
  7. 7.ICVS/3B’s – PT Government Associate LaboratoryBraga/GuimarãesPortugal

Personalised recommendations